Mode
Text Size
Log in / Sign up
N/A Completed N=53 Randomized Double-blind Treatment

Comparison of New Contact Lens With Current Marketed Lens

Source: ClinicalTrials.gov NCT03360110 ↗
Enrolled (actual)
53
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcomePrimary: Corneal Staining Extent — 0.04; 0.04 units on a scale

Summary

The purpose of this study is to validate the clinical performance of a new contact lens design.

Outcome Measures

OutcomeResultp-value
PRIMARY
Corneal Staining Extent
0.07; 0.07
PRIMARY
Conjunctival Staining Score
0.26; 0.29
PRIMARY
Palpebral Hyperemia on Upper Lid
1.05; 1.06
PRIMARY
Palpebral Hyperemia on Lower Lid
1.05; 1.06
PRIMARY
Palpebral Roughness Grade - Upper Lid
1.26; 1.20
PRIMARY
Palpebral Roughness Grade - Lower Lid
1.23; 1.20
SECONDARY
Distance Visual Acuity
-0.23; -0.22; -0.04; -0.04
SECONDARY
Near Visual Acuity
-0.17; -0.19; 0.06; 0.04
SECONDARY
Vision Quality Rating
9.3; 9.2

Eligibility Criteria

Inclusion criteria

A person is eligible for inclusion in the study if he/she:

  • Between and 18 and 35 years of age and has full legal capacity to volunteer
  • Has had a self-reported oculo-visual examination in the last two years
  • Has read and understood the information consent letter
  • Is willing and able to follow instructions and maintain the appointment schedule
  • Is correctable to a visual acuity of 20/25 or better (in each eye) with their habitual correction or 20/20 best corrected
  • Has a Contact Lens Refraction between -1.00D and -6.00D
  • Cylinder power ≤ -0.75DC in Spherical Cylindrical Refraction
  • Currently wears soft contact lenses
  • Is willing to wear lenses for a minimal of 8 hours a day and everyday during the course of the study
  • Has clear corneas and no active ocular disease
  • Has not worn lenses for at least 12 hours before the first visit

Exclusion Criteria

A person will be excluded from the study if he/she:

  • Has never worn contact lenses before
  • Is wearing Monovision modality
  • Has any systemic disease affecting ocular health
  • Is using any systemic or topical medications that will affect ocular health
  • Has any ocular pathology or severe insufficiency of lacrimal secretion (moderate to severe dry eyes) that would affect the wearing of contact lenses
  • Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye
  • Has any clinically significant lid or conjunctival abnormalities, active neovascularization or any central corneal scars
  • Is aphakic
  • Has undergone corneal refractive surgery
  • Is participating in any other type of eye related clinical or research study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03360110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search